Chemistry:Alisporivir
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| ATC code |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| NIAID ChemDB | |
| Chemical and physical data | |
| Formula | C63H113N11O12 |
| Molar mass | 1216.662 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
Alisporivir (INN), or Debio 025, DEB025, (or UNIL-025) is a cyclophilin inhibitor.[1] Its structure is reminiscent of, and synthesized from ciclosporin.[citation needed]
It inhibits cyclophilin A.[2] Alisporivir is not immunosuppressive.[3]
It is being researched for potential use in the treatment of hepatitis C.[4][5] It has also been investigated for Duchenne muscular dystrophy[1] and may have therapeutic potential in Alzheimer's disease.[6]
Alisporivir is under development by Debiopharm for Japan and by Novartis for the rest of the world (licence granted by Debiopharm) since February 2010.[citation needed]
References
- ↑ 1.0 1.1 "Investigation of Debio 025, a cyclophilin inhibitor, in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy". British Journal of Pharmacology 155 (4): 574–584. October 2008. doi:10.1038/bjp.2008.285. PMID 18641676.
- ↑ "Profile of alisporivir and its potential in the treatment of hepatitis C". Drug Design, Development and Therapy 7: 105–115. 15 February 2013. doi:10.2147/DDDT.S30946. PMID 23440335.
- ↑ "Inhibition of human immunodeficiency virus type 1 replication in human cells by Debio-025, a novel cyclophilin binding agent". Antimicrobial Agents and Chemotherapy 52 (4): 1302–1317. April 2008. doi:10.1128/AAC.01324-07. PMID 18212100.
- ↑ "The non-immunosuppressive cyclosporin DEBIO-025 is a potent inhibitor of hepatitis C virus replication in vitro". Hepatology 43 (4): 761–770. April 2006. doi:10.1002/hep.21102. PMID 16557546.
- ↑ "Debio 025, a cyclophilin binding molecule, is highly efficient in clearing hepatitis C virus (HCV) replicon-containing cells when used alone or in combination with specifically targeted antiviral therapy for HCV (STAT-C) inhibitors". Antimicrobial Agents and Chemotherapy 53 (3): 967–976. March 2009. doi:10.1128/AAC.00939-08. PMID 19104013.
- ↑ "USC study reveals potential new treatment target for Alzheimer's disease | Keck School of Medicine of USC" (in en-US). 14 June 2021. https://keck.usc.edu/usc-study-reveals-potential-new-treatment-target-for-alzheimers-disease/.
 |  |
